Contributor Page
Smart & Biggar/Fetherstonhaugh
 
Email  |  Website  |  Articles
Contact Details
Tel: +1 416 5935514
Fax: +1 416 5911690
1100-150 York Street
Toronto
ON M5H 3S5
Canada
By Mark Biernacki, Guillaume Lavoie Ste-Marie, Joshua Neubarth
In most jurisdictions, copyright owners often face numerous challenges when seeking to enforce their rights against media pirates.
By Daniel Anthony, Jamie-Lynn Kraft
As trade talks between Canada and the United States dominate the headlines, it is hard to ignore the strong economic ties between these neighbouring nations.
By Brandon Heard
On April 23, 2018, the Competition Bureau announced an agreement whereby Metro will sell properties/leases and take steps to terminate agreements relating to pharmacies in certain Quebec markets.
By Brandon Heard
The balance of Pfizer's motion to dismiss has been deferred to the trial in the liability phase of the proceeding.
By Andrew Mandlsohn
Eli Lilly seeks leave in olanzapine section 8 damages action.
By Abigail Smith
The report of the Working Group will be presented to the PMPRB for consideration prior to the publication of draft Guidelines in the fall, followed by a further period of consultation.
By Lynn Ing
These provisions will not come into force until October 23, 2018.
By Katie Lee
Eliminate the requirement for filing clinical case reports in a filed submission or supplement, unless requested by the Minister, in order to alleviate administrative burden.
By Katie Lee
We will continue to report updates as further regulations and guidance arise.
By Brandon Heard
The appellants argued that Apo-Lansoprazole could not and would not have received regulatory approval in April 2007 and Apotex was not entitled to damages.
By Abigail Smith
The following reports on two court decisions addressing procedure under these amendments.
By Lynn Ing
Justice Locke also held that AstraZeneca was entitled to a declaration of infringement and ordered the quantification of AstraZeneca's damages or Apotex's profits.
By Andrew Mandlsohn
Health Canada intends to pre-publish the proposed regulatory amendments in 2019.
By Andrew Mandlsohn
The Government intends to publish final regulations as soon as possible following Royal Assent of the Cannabis Act.
By Brandon Heard
Implementation will occur in 4 phases to take place over 4 years.